# MedImmune LLC clinical trials: 270 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 270 trials with MedImmune LLC as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by MedImmune LLC: 270 rows for $13.50, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/medimmune-llc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 270
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 270, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 21, 2020 | NCT04522323 | A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma | MedImmune LLC | Phase 1 | Active not recruiting | Advanced Renal Cell Carcinoma | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04522323) |
| February 7, 2020 | NCT04261075 | IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. | MedImmune LLC | Phase 1 | Completed | Advanced Solid Tumors | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04261075) |
| October 30, 2019 | NCT04145193 | Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC | MedImmune LLC | Phase 2 | Withdrawn | Microsatellite-stable Colorectal Cancer | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04145193) |
| September 16, 2019 | NCT04091373 | A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide | MedImmune LLC | Phase 1 | Completed | Type 2 Diabetes Mellitus | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04091373) |
| August 28, 2019 | NCT04068610 | COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC | MedImmune LLC | Phase 1/2 | Active not recruiting | Metastatic Microsatellite-stable Colorectal Cancer | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04068610) |
| July 15, 2019 | NCT04019561 | A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH. | MedImmune LLC | Phase 2 | Completed | Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04019561) |
| May 13, 2019 | NCT03946800 | A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors | MedImmune LLC | Phase 1 | Completed | Solid Tumors, Cancer | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03946800) |
| April 4, 2019 | NCT03903718 | Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza | MedImmune LLC | Phase 2 | Withdrawn | Influenza | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03903718) |
| March 26, 2019 | NCT03889275 | A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors | MedImmune LLC | Phase 1 | Completed | Advanced Solid Tumors | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03889275) |
| January 30, 2019 | NCT03822351 | Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC | MedImmune LLC | Phase 2 | Completed | Stage III Non-small Cell Lung Cancer, Unresectable | 189 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03822351) |
| January 22, 2019 | NCT03811652 | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | MedImmune LLC | Phase 1 | Completed | Non Small Cell Lung Cancer Squamous (NSCLC-Sq), Head and Neck Squamous Cell Carcinoma (HNSCC), Small Cell Lung Cancer... | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03811652) |
| January 7, 2019 | NCT03794544 | Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer | MedImmune LLC | Phase 2 | Completed | Resectable, Early-stage, NSCLC | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03794544) |
| November 19, 2018 | NCT03745937 | A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus | MedImmune LLC | Phase 2 | Completed | Type 2 Diabetes Mellitus | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03745937) |
| August 31, 2018 | NCT03654313 | Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus | MedImmune LLC | Phase 1 | Completed | Atherosclerosis, Cardiovascular Disease | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03654313) |
| August 10, 2018 | NCT03625778 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese Participants | MedImmune LLC | Phase 1 | Completed | Obesity | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03625778) |
| August 2, 2018 | NCT03611556 | MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study. | MedImmune LLC | Phase 1/2 | Completed | Carcinoma, Metastatic Pancreatic Adenocarcinoma | 213 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03611556) |
| July 23, 2018 | NCT03596177 | A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes Mellitus | MedImmune LLC | Phase 2 | Completed | Diabetes Mellitus, Type II, Obesity | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03596177) |
| July 6, 2018 | NCT03578809 | A Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction | MedImmune LLC | Phase 2 | Completed | ST Elevation Myocardial Infarction | 593 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03578809) |
| June 20, 2018 | NCT03564444 | D2560C00015 FluMist Annual Safety Study 2018 | MedImmune LLC | Phase 4 | Completed | Influenza, Healthy | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03564444) |
| June 14, 2018 | NCT03555994 | A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. | MedImmune LLC | Phase 2 | Completed | Type 2 Diabetes Mellitus | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03555994) |
| June 8, 2018 | NCT03550378 | A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That... | MedImmune LLC | Phase 2 | Completed | Type II Diabetes Mellitus, Renal Insufficiency | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03550378) |
| May 21, 2018 | NCT03530397 | A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors | MedImmune LLC | Phase 1 | Active not recruiting | Selected Advanced Solid Tumors | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03530397) |
| April 5, 2018 | NCT03489525 | MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma | MedImmune LLC | Phase 1 | Completed | Relapsed/Refractory Multiple Myeloma | 107 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03489525) |
| February 23, 2018 | NCT03444584 | Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes | MedImmune LLC | Phase 2 | Completed | Type 2 Diabetes Mellitus | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03444584) |
| December 28, 2017 | NCT03385369 | A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent | MedImmune LLC | Phase 1 | Completed | Safety, Healthy Subjects | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03385369) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 106 |
| Phase 1/2 | 25 |
| Phase 2 | 77 |
| Phase 2/3 | 2 |
| Phase 3 | 25 |
| Phase 4 | 15 |
| Not applicable | 1 |
| Observational | 19 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 232 |
| Terminated | 23 |
| Withdrawn | 7 |
| Active not recruiting | 7 |
| Suspended | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Influenza, Human | 41 |
| Asthma | 23 |
| Neoplasms | 19 |
| Diabetes Mellitus, Type 2 | 11 |
| Respiratory Syncytial Virus Infections | 10 |
| Carcinoma, Non-Small-Cell Lung | 9 |
| Arthritis, Rheumatoid | 8 |
| Leukemia | 7 |
| Pulmonary Disease, Chronic Obstructive | 7 |
| Lymphoma, Non-Hodgkin | 7 |
| Neoplasm Metastasis | 6 |
| Lymphoma | 6 |
| Lupus Erythematosus, Systemic | 6 |
| Recurrence | 5 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 5 |
| Melanoma | 4 |
| Atherosclerosis | 4 |
| Obesity | 4 |
| Lymphoma, Large B-Cell, Diffuse | 4 |
| Diabetes Mellitus, Insulin-Dependent, 12 | 4 |
| Diabetes Mellitus | 4 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 |
| Psoriasis | 3 |
| Dermatitis, Atopic | 3 |
| Pneumonia | 3 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Doner kebab restaurants in the United States](https://specstream.ai/data/businesses/doner-kebab-restaurants/united-states)
- [Promotional products companies in the United States](https://specstream.ai/data/businesses/promotional-products-companies/united-states)
- [Cigar bars in the United States](https://specstream.ai/data/businesses/cigar-bars/united-states)
- [Otology practices in the United States](https://specstream.ai/data/businesses/otology-practices/united-states)
- [Bearing suppliers in the United States](https://specstream.ai/data/businesses/bearing-suppliers/united-states)
- [Marketing agencies in the United States](https://specstream.ai/data/businesses/marketing-agencies/united-states)
